SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 25.19 |
| Enterprise Value ($M) | -73.13 |
| Book Value ($M) | 91.99 |
| Book Value / Share | 25.67 |
| Price / Book | 0.26 |
| NCAV ($M) | 91.99 |
| NCAV / Share | 24.29 |
| Price / NCAV | 0.27 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.15 |
| Return on Assets (ROA) | -1.25 |
| Return on Equity (ROE) | -1.80 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 38.95 |
| Current Ratio | 38.95 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 96.69 |
| Assets | 96.69 |
| Liabilities | 4.69 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -19.49 |
| Net Income | -17.60 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 99.87 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | S.H.N. Financial Investments Ltd. | 4.99 | 67.34 | |
| 13G/A | Janus Henderson Group Plc | 5.40 | -46.32 | |
| 13G/A | Dellora Investments LP | 10.30 | ||
| 13G | Lind Global Fund II LP | 9.90 | ||
| 13G/A | CVI Investments, Inc. | 0.00 | -100.00 | |
| 13G/A | Stonepine Capital Management, LLC | 9.99 | 0.00 | |
| 13G | Adage Capital Management, L.P. | 9.99 | ||
| 13G | Price T Rowe Associates Inc /md/ | 19.99 | ||
| 13G | Venrock Healthcare Capital Partners III, L.P. | 9.99 | ||
| 13G | Biotechnology Value Fund L P | 9.99 | ||
| 13G | Vivo Opportunity Fund Holdings, L.P. | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| rrrr UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C., 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C., 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 554 | 3,778 | 14.66 | |
| 6,425 | 51,122 | 12.57 | |
| 13,334 | 100,977 | 13.20 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SYBX – Synlogic, Inc. | TCRT – Alaunos Therapeutics, Inc. |
| TELO – Telomir Pharmaceuticals, Inc. | TGTX – TG Therapeutics, Inc. |
| THAR – Tharimmune, Inc. |